血塞通、辛伐他汀联合氨氯地平治疗冠心病并发脑梗死的疗效

Efficiency of Xuesaitong combined with simvastatin and amlodipine in the treatment of patients with coronary heart disease complicated with cerebral infarction

目的探讨血塞通、辛伐他汀联合氨氯地平治疗冠心病并发脑梗死的临床疗效以及安全性。方法选取冠心病并发脑梗死患者180例,随机分为对照组和观察组各90例。对照组采用辛伐他汀联合氨氯地平治疗,观察组采用血塞通、辛伐他汀、氨氯地平联合治疗。比较2组患者治疗前后神经功能、血液流变学指标以及神经功能缺损的情况。比较2组的疗效及不良反应的发生情况。结果治疗后,观察组欧洲卒中量表(ESS)评分显著高于对照组(P <0. 05)。治疗后,2组患者的血液流变学指标均明显降低,观察组全血黏度、红细胞压积以及纤维蛋白原水平显著低于对照组(P <0. 05)。观察组优良率达到85. 55%,显著高于对照组的64. 45%(P <0. 01)。观察组患者不良反应的发生率显著低于对照组(P <0. 05)。结论血塞通、辛伐他汀联合氨氯地平治疗冠心病并发脑梗死疗效显著,可以减少神经细胞损伤,降低不良发生发生率。

Objective To explore the clinical efficacy and safety of Xuesaitong combined with simvastatin and amlodipine in the treatment of patients with coronary heart disease and cerebral infarction. Methods Totally 180 patients with coronary heart disease and cerebral infarction were selected and randomly divided into control group and observation group, 90 cases in each group. The control group was treated with simvastatin and amlodipine, while the observation group was treated with Xuesaitong, simvastatin and amlodipine. The changes of neural function, hemorheology index and neural function defect were compared between the two groups. Clinical efficacy and adverse reactions were compared between the two groups. Results After treatment, the European Stroke Scale （ESS） score in the observation group was significantly higher than that in the control group （ P 〈 0.05）. After treatment, the hemorheological indexes in both groups were significantly lower than those before treatment, and the whole blood viscosity, hematocrit and fibrinogen levels of the observation group were significantly lower than those of the control group （ P 〈0.05）. The excellent rate of the observation group was 85.55%, which was significantly higher than 64.45% of the control group （ P 〈0.01）. The incidence rate of adverse reactions in the observation group was significantly lower than that in the control group （ P 〈0.05）. Conclusion The combined treatment of Xuesaitong, simvastatin and amlodipine for patients with coronary heart disease and cerebral infarction can improve the clinical efficacy and reduce the incidence rate of adverse reactions.